Prolia Treatment - Case Study 4 | Osteoporosis | Amgen

Is this your next Prolia® patient?

75-year-old woman who has been receiving Prolia for 3 years.
75-year-old woman who has been receiving Prolia® for 3 years
  • No history of previous fracture
  • Began treatment with Prolia® 3 years ago after FRAX® and DXA assessments indicated she was at high risk of fracture
  • Recent DXA scan revealed bone mineral density T-score –2.6 at the hip

Criteria: Why should she continue Prolia®?

  • Osteoporosis is a chronic condition and continued treatment is necessary for many patients to sustain therapeutic benefits1,2
  • Patients aged >70 years and/or with hip bone mineral density T-score <-2.5 are defined as having high risk for fracture2,3
  • 10 years of Prolia® is associated with a favourable benefit/risk profile:4
    • Sustained low incidence of fractures
    • Continuous increases in bone mineral density
    • Well tolerated
  • Prolia® is associated with better persistence than oral bisphosphonates5–8
DXA: dual x-ray absorptiometry; FRAX: fracture risk assessment tool.
  1. Brown JP, et al. J Bone Miner Res. 2013;28:746–52.
  2. Tsourdi E, et al. Bone. 2017;105:11–7.
  3. Adler RA, et al. J Bone Miner Res. 2016;31:16–35.
  4. Bone HG, et al. Lancet Diabetes Endocrinol. 2017;5:513–23.
  5. Reyes C, et al. Osteoporos Int. 2017;28:2297–3004.
  6. Hadji P, et al. Osteoporos Int. 2016;27:2967–78.
  7. Karlsson L, et al. Osteoporos Int. 2015;26:2401–11.
  8. Durden E, et al. Arch Osteoporos. 2017;12:22–30.


The information contained in this site is for healthcare professionals only

I am a patient
I am a member of the public